OABIW
OmniAb Inc.Key Statistics
About OmniAb Inc.
OmniAb Inc. is a pioneering biotechnology firm specializing in the discovery and development of fully human therapeutic antibodies using its proprietary OmniAb platform, which boasts a broad range of antibody libraries. Targeting critical therapeutic areas including oncology and autoimmune disorders, OmniAb is positioned at the forefront of the dynamic biopharmaceutical landscape. The company has cultivated a strong pipeline of innovative products and strategic collaborations, enabling it to leverage the surging demand for advanced antibody therapies and play a vital role in the evolution of personalized medicine to enhance patient outcomes.
Fundamentals
| Revenue (TTM) | $38.46M |
| Gross Profit (TTM) | $37.79M |
| EBITDA | $-21.60M |
| Operating Margin | -49.50% |
| Return on Equity | -17.00% |
| Return on Assets | -8.35% |
| Revenue/Share (TTM) | $0.31 |
| Book Value | $1.79 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 244.20% |
| Shares Outstanding | 0 |
| Float | $118.25M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OABIW and any ticker you trade — then tracks every position and per-strategy win rate.